Does extended interval Ocrelizumab dosing differ from regular dosing in clinical and laboratory outcomes at 2-year follow-up?
By Valeria Pozzilli, Clinical fellow, national hospital for neurology and neurosurgery & Riccardo Nistri, Clinical research assistant, University College London Hospitals NHS Foundation Trust
Project poster
Project write up
More MS Academy Medication Projects
DMT switch from natalizumab to ocrelizumab or fingolimod in relapsing remitting MS patients: a retrospective study to measure outcome
By Sanjida Chowdhury, Specialty registrar, Nottingham University Hospitals NHS Trust & Dr Shahjalal Khan, Neurology registrar, Nottingham University Hospitals NHS Trust
Natalizumab safety monitoring audit
By Zeinab Hamed, Speciality registrar, Sheffield teaching hospital
A Therapy led Sativex service – a retrospective audit of patient outcomes
By Jenny Thain, MS clinical specialist physiotherapist, The Walton Centre Liverpool
Encouraging excellence, developing leaders, inspiring change
MS Academy was established five years ago and in that time has accomplished a huge amount. The six different levels of specialist MS training are dedicated to case-based learning and practical application of cutting edge research. Home to national programme Raising the Bar and the fantastic workstream content it is producing, this is an exciting Academy to belong to.